Sanofi Launches Diabetes Drug Soliqua in India
By Rediff Money Desk, NEWDELHI Apr 30, 2024 12:38
Sanofi India has launched its diabetes drug Soliqua, a combination of insulin glargine and lixisenatide, offering a once-daily injectable treatment option for adults with type 2 diabetes.
![Sanofi Launches Diabetes Drug Soliqua in India](https://im.rediff.com/money/2018/mar/08drugs.jpg)
New Delhi, Apr 30 (PTI) Sanofi India on Tuesday said it has launched its diabetes drug Soliqua in the country.
The company introduced the medication after receiving the marketing authorisation from the Central Drugs Standard Control Organization (CDSCO) earlier last year.
Soliqua is a once-daily injectable combination drug containing insulin, glargine 100 units/ml, which is a long-acting basal insulin and lixisenatide, a GLP-1 receptor agonist.
It is available at a therapy cost of Rs 1,850 per pen.
"The inclusion of Soliqua to our comprehensive diabetes portfolio (orals and injectables) eases therapy initiation, which helps those prescribed, keep their blood sugar in control more effectively," Sanofi India Head Diabetes Business Unit Cyrus Aibara said in a statement.
Soliqua is indicated as a treatment in adults with obesity and type 2 diabetes mellitus, to improve glycemic control as an adjunct to diet and exercise, in those who are insufficiently controlled on oral or injectable therapies.
The company introduced the medication after receiving the marketing authorisation from the Central Drugs Standard Control Organization (CDSCO) earlier last year.
Soliqua is a once-daily injectable combination drug containing insulin, glargine 100 units/ml, which is a long-acting basal insulin and lixisenatide, a GLP-1 receptor agonist.
It is available at a therapy cost of Rs 1,850 per pen.
"The inclusion of Soliqua to our comprehensive diabetes portfolio (orals and injectables) eases therapy initiation, which helps those prescribed, keep their blood sugar in control more effectively," Sanofi India Head Diabetes Business Unit Cyrus Aibara said in a statement.
Soliqua is indicated as a treatment in adults with obesity and type 2 diabetes mellitus, to improve glycemic control as an adjunct to diet and exercise, in those who are insufficiently controlled on oral or injectable therapies.
Read More On:
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Vodafone Idea L
- 17.90 ( -3.35)
- 166585989
- Alstone Textiles
- 0.75 (+ 8.70)
- 47681821
- GTL Infrastructure
- 3.27 (+ 4.81)
- 44040612
- Visagar Financial
- 0.91 (+ 12.35)
- 29755394
- YES Bank Ltd.
- 23.70 (+ 0.77)
- 22163699
MORE NEWS
![Indian Economy...](https://im.rediff.com/80-80/money/2020/nov/22economy.jpg)
Indian Economy Growth: Exports, Manufacturing &...
Mumbai, June 30 (PTI) Healthy increase in the country's exports, improvement in the...
![India Launches...](https://im.rediff.com/80-80/news/2020/jul/imports-o.jpg)
India Launches Anti-Dumping Probe on Glass...
New Delhi, June 30 (PTI) India has initiated an anti-dumping probe into the import of...
![IBBI Launches...](https://im.rediff.com/80-80/money/2020/dec/16insolvency.jpg)
IBBI Launches Electronic Forms for Liquidation...
New Delhi, Jun 30 (PTI) To ease the compliance burden for insolvency professionals, and...